Triple-Drug cocktail shows promise for tough stomach cancers
NCT ID NCT05394740
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tested a combination of three drugs—regorafenib, nivolumab, and chemotherapy—in 30 people with advanced or recurrent stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery. The goal was to see if the combination was safe and effective at shrinking tumors. Participants received the drugs in cycles, and researchers measured side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
Conditions
Explore the condition pages connected to this study.